COVID-19 (Coronavirus): ADB's Response

ADB is supporting its developing members in responding to the COVID-19 pandemic through finance, knowledge, and partnerships.

In the Spotlight


publication | 28 October 2022

COVID-19 and the Deployment of Labor Migrants from Asia: Lessons Learned and Ways Forward

This brief analyzes how the COVID-19 pandemic has impacted labor migrants in Asia and the Pacific, assesses the socioeconomic vulnerabilities it exposed, and lays out steps to better protect overseas workers.


photo essay | 07 February 2023

Community-Based Partnerships Lift Up Mongolia’s COVID-19-Affected People

The COVID-19 pandemic has significantly affected many of the world’s poorest and most vulnerable people. With many governments under severe resource constraints, civil society organizations (CSOs) have often played a critical role in filling social assistance gaps. In Mongolia, ADB is working with CSOs to provide alternative livelihood programs for families and communities affected by the pandemic. Read their stories in this photo essay.


publication | 16 September 2022

Health Security Interventions for COVID-19 Response: Guidance Note

This guidance note is designed to help developing member countries of the Asian Development Bank strengthen their health systems and security as they recover from the impact of COVID-19.


article | 13 September 2021

ADB’s COVID-19 Response for Developing Asia Surpasses $20 Billion

ADB’s committed assistance to help its developing member countries address the COVID-19 pandemic including vaccination support has surpassed $20 billion

ADB’s COVID-19 response consists of a $20 billion package announced in April 2020 and the $9 billion Asia Pacific Vaccine Access Facility (APVAX) announced in December 2020.

ADB’s initial $20 billion COVID-19 response package supports its developing member countries in countering the severe macroeconomic and health impacts caused by COVID-19, including $2.5 billion in concessional and grant resources, as well as $2 billion earmarked for the private sector (non-sovereign).

ADB's $9 billion APVAX vaccine initiative offers rapid and equitable support to its developing member countries as they procure and deliver effective and safe COVID-19 vaccines.

Committed Amount is the financing approved by ADB's Board of Directors or Management for which the legal agreement has been signed by the borrower, recipient, or the investee company and ADB.
*Projects may be listed in more than one country or subregion. The number of projects excludes short-term finance transactions under the Trade Finance, Supply Chain Finance, and Microfinance Programs.

News and Multimedia   Subscribe to our newsletter

Publications and Documents